Research and Development of Antibiotics: The Next Battleground

ACS Infectious Diseases

Volumn 1, Issue 6, 2016, Pages 232-233

  Shlaes, David M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; DAPTOMYCIN; LINEZOLID;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; COMMUNITY ACQUIRED PNEUMONIA; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SOFT TISSUE INFECTION;

EID: 84955292686     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.5b00048     Document Type: Short Survey

References (7)

1. Shlaes, D. M. Antibiotics: The Perfect Storm; Springer-Verlag, 2010.
2. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007) Drugs For Bad Bugs: Confronting The Challenges of Antibacterial Discovery Nat. Rev. Drug Discovery 6 (January) 29 10.1038/nrd2201
3. Shlaes, D. M., Sahm, D., Opiela, C., and Spellberg, B. (2013) The FDA reboot of antibiotic development Antimicrob. Agents Chemother. 57, 4605-7 10.1128/AAC.01277-13
4. Guidance for Industry Antibacterial Therapies for Patients With Unmet Medical Need for the Treatment of Serious Bacterial Diseases. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM359184.pdf.
5. Mossialos, E., Morel, C., Edwards, S., Berenson, J., Gemmill-Toyama, M., and Brogan, D. Policies and Incentives for Promoting Innovation in Antibiotic Research. http://www.lse.ac.uk/intranet/LSEServices/ERD/pressAndInformationOffice/PDF/Policiesandincentivesforpromotinginnovationinantibiotic.pdf.
6. Outterson, K. New Business models for Sustainable Antibiotics; http://www.chathamhouse.org/sites/files/chathamhouse/public/Research/Global%20Health/0214SustainableAntibiotics.pdf.
7. Spellberg, B. and Rex, J. H. (2013) The Value of Single-Pathogen Antibacterial Agents Nat. Rev. Drug Discovery 12, 963 10.1038/nrd3957-c1